HK1252799A1 - 封端和未封端的抗體半胱氨酸,及其在抗體-藥物綴合中的用途 - Google Patents
封端和未封端的抗體半胱氨酸,及其在抗體-藥物綴合中的用途Info
- Publication number
- HK1252799A1 HK1252799A1 HK18112100.2A HK18112100A HK1252799A1 HK 1252799 A1 HK1252799 A1 HK 1252799A1 HK 18112100 A HK18112100 A HK 18112100A HK 1252799 A1 HK1252799 A1 HK 1252799A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- antibody
- capped
- uncapped
- cysteines
- drug conjugation
- Prior art date
Links
- 229940125644 antibody drug Drugs 0.000 title 1
- 230000021615 conjugation Effects 0.000 title 1
- 235000018417 cysteine Nutrition 0.000 title 1
- 150000001945 cysteines Chemical class 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/05—Dipeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
- A61K47/6817—Toxins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
- A61K47/6855—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from breast cancer cell
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Cell Biology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Oncology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562204005P | 2015-08-12 | 2015-08-12 |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1252799A1 true HK1252799A1 (zh) | 2019-06-06 |
Family
ID=56855760
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK18112100.2A HK1252799A1 (zh) | 2015-08-12 | 2018-09-20 | 封端和未封端的抗體半胱氨酸,及其在抗體-藥物綴合中的用途 |
Country Status (20)
Country | Link |
---|---|
US (2) | US10653794B2 (zh) |
EP (2) | EP3334760B1 (zh) |
JP (2) | JP6865209B2 (zh) |
KR (2) | KR102146617B1 (zh) |
CN (1) | CN107849121B (zh) |
AU (1) | AU2016305331B2 (zh) |
BR (1) | BR112018001904A2 (zh) |
CA (1) | CA2938333A1 (zh) |
DK (1) | DK3334760T3 (zh) |
ES (1) | ES2864842T3 (zh) |
HK (1) | HK1252799A1 (zh) |
HR (1) | HRP20210579T1 (zh) |
HU (1) | HUE053956T2 (zh) |
IL (1) | IL257420B (zh) |
MX (1) | MX2018001686A (zh) |
PL (1) | PL3334760T3 (zh) |
PT (1) | PT3334760T (zh) |
RU (2) | RU2742260C2 (zh) |
SI (1) | SI3334760T1 (zh) |
WO (1) | WO2017025897A2 (zh) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2742260C2 (ru) * | 2015-08-12 | 2021-02-04 | Пфайзер Инк. | Кэпированные и некэпированные цистеины антитела и их применение в конъюгации антитело-лекарственное средство |
EP3580234A1 (en) * | 2017-02-08 | 2019-12-18 | Pfizer Inc. | Large scale production process for capped and un-capped antibody cysteines and their use in therapeutic protein conjugation |
KR20210125034A (ko) | 2019-02-15 | 2021-10-15 | 우시 바이올로직스 아일랜드 리미티드 | 동질성이 개선된 항체-약물 콘쥬게이트의 제조방법 |
EP4267616A1 (en) * | 2020-12-22 | 2023-11-01 | Novartis AG | Methods for reducing the oxidation level of cysteine residues in a secreted recombinantly-expressed protein during cell culture |
WO2023067626A1 (en) * | 2021-10-20 | 2023-04-27 | Dr. Reddy's Laboratories Limited | A cell culture process to produce an antibody composition |
Family Cites Families (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5241078A (en) * | 1988-06-14 | 1993-08-31 | Cetus Oncology | Coupling agents and sterically hindered disulfide linked conjugates prepared therefrom |
WO1993006217A1 (en) * | 1991-09-19 | 1993-04-01 | Genentech, Inc. | EXPRESSION IN E. COLI OF ANTIBODY FRAGMENTS HAVING AT LEAST A CYSTEINE PRESENT AS A FREE THIOL, USE FOR THE PRODUCTION OF BIFUNCTIONAL F(ab')2 ANTIBODIES |
JP2002534119A (ja) * | 1999-01-14 | 2002-10-15 | ボルダー バイオテクノロジー, インコーポレイテッド | 自由システイン残基を有するタンパク質の生産方法 |
AU2002354363A1 (en) * | 2001-12-04 | 2003-06-17 | Mitsubishi Pharma Corporation | Method of activating protein |
EP1893632B1 (en) * | 2005-06-17 | 2015-08-12 | Novo Nordisk Health Care AG | Selective reduction and derivatization of engineered factor vii proteins comprising at least one non-native cysteine |
AU2007267798A1 (en) * | 2006-05-26 | 2007-12-06 | Ipsen Pharma S.A.S. | Methods for site-specific pegylation |
KR101643514B1 (ko) * | 2007-07-09 | 2016-07-27 | 제넨테크, 인크. | 폴리펩티드의 재조합 생산 동안의 디술피드 결합 환원의 방지 |
CN102083460A (zh) * | 2008-01-18 | 2011-06-01 | 米迪缪尼有限公司 | 用于位点特异性偶联的半胱氨酸工程化抗体 |
US8883999B2 (en) * | 2008-03-19 | 2014-11-11 | Intelligent Bio Systems, Inc. | Methods and solutions for inhibiting undesired cleaving of labels |
SG176947A1 (en) | 2009-07-03 | 2012-01-30 | Avipep Pty Ltd | Immuno-conjugates and methods for producing them |
WO2011041721A1 (en) * | 2009-10-02 | 2011-04-07 | Biogen Idec Ma Inc. | Methods of preventing and removing trisulfide bonds |
KR20120123299A (ko) * | 2009-12-04 | 2012-11-08 | 제넨테크, 인크. | 다중특이적 항체, 항체 유사체, 조성물 및 방법 |
CA3220104A1 (en) * | 2010-06-08 | 2011-12-15 | Genentech, Inc. | Cysteine engineered antibodies and conjugates |
RU2018119112A (ru) * | 2011-05-27 | 2018-11-07 | Эббви Байотекнолоджи Лтд. | Композиции и способы на основе dac hyp |
KR101541764B1 (ko) * | 2012-02-24 | 2015-08-05 | (주)알테오젠 | 시스테인 잔기를 포함하는 모티프가 결합된 변형항체, 상기 변형항체를 포함하는 변형항체-약물 접합체 및 그 제조방법 |
WO2014052650A2 (en) | 2012-09-26 | 2014-04-03 | Massachusetts Institute Of Technology | Modification of peptides via snar reactions of thiols with fluorinated aromatics |
PE20161413A1 (es) * | 2013-11-04 | 2017-01-10 | Stemcentrx Inc | Conjugados de anticuerpo anti-efna4-farmaco |
EP3077522A1 (en) * | 2013-12-04 | 2016-10-12 | Immunogen, Inc. | Compositions and methods for antibody production |
CA2937731C (en) | 2014-01-27 | 2019-09-24 | Pfizer Inc. | Bifunctional cytotoxic agents |
SG11201706991YA (en) | 2015-03-20 | 2017-10-30 | Pfizer | Bifunctional cytotoxic agents containing the cti pharmacophore |
RU2742260C2 (ru) * | 2015-08-12 | 2021-02-04 | Пфайзер Инк. | Кэпированные и некэпированные цистеины антитела и их применение в конъюгации антитело-лекарственное средство |
-
2016
- 2016-08-09 RU RU2018105128A patent/RU2742260C2/ru active
- 2016-08-09 US US15/748,268 patent/US10653794B2/en active Active
- 2016-08-09 PT PT167605484T patent/PT3334760T/pt unknown
- 2016-08-09 IL IL257420A patent/IL257420B/en unknown
- 2016-08-09 EP EP16760548.4A patent/EP3334760B1/en active Active
- 2016-08-09 AU AU2016305331A patent/AU2016305331B2/en active Active
- 2016-08-09 KR KR1020187006927A patent/KR102146617B1/ko active IP Right Grant
- 2016-08-09 CN CN201680047377.XA patent/CN107849121B/zh active Active
- 2016-08-09 MX MX2018001686A patent/MX2018001686A/es unknown
- 2016-08-09 BR BR112018001904A patent/BR112018001904A2/pt active Search and Examination
- 2016-08-09 WO PCT/IB2016/054789 patent/WO2017025897A2/en active Application Filing
- 2016-08-09 PL PL16760548T patent/PL3334760T3/pl unknown
- 2016-08-09 EP EP20207006.6A patent/EP3808768A1/en active Pending
- 2016-08-09 HU HUE16760548A patent/HUE053956T2/hu unknown
- 2016-08-09 DK DK16760548.4T patent/DK3334760T3/da active
- 2016-08-09 CA CA2938333A patent/CA2938333A1/en active Pending
- 2016-08-09 JP JP2018506438A patent/JP6865209B2/ja active Active
- 2016-08-09 SI SI201631163T patent/SI3334760T1/sl unknown
- 2016-08-09 RU RU2021101009A patent/RU2021101009A/ru unknown
- 2016-08-09 KR KR1020207023230A patent/KR102319622B1/ko active IP Right Grant
- 2016-08-09 ES ES16760548T patent/ES2864842T3/es active Active
-
2018
- 2018-09-20 HK HK18112100.2A patent/HK1252799A1/zh unknown
-
2020
- 2020-03-03 US US16/807,375 patent/US11980669B2/en active Active
-
2021
- 2021-04-05 JP JP2021063975A patent/JP2021118694A/ja active Pending
- 2021-04-12 HR HRP20210579TT patent/HRP20210579T1/hr unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1243414A1 (zh) | 苯並呋喃類衍生物、其製備方法及其在醫藥上的應用 | |
IL267323A (en) | Thienopyrrole derivatives for use in targeting proteins, compositions, methods, and uses thereof | |
HK1231367A1 (zh) | 抗體藥物偶聯物、試劑和製備方法及其治療用途 | |
IL248239A0 (en) | Drug conjugates - antibody against - her3, preparations containing them and their uses | |
IL247248A0 (en) | Anti-dll3 antibodies and drug conjugates for use in melanoma | |
HK1252799A1 (zh) | 封端和未封端的抗體半胱氨酸,及其在抗體-藥物綴合中的用途 | |
IL256726A (en) | Bisphosphonate-hbed, their radiometallic conjugates and their use as transnasal agents | |
GB2562059B (en) | Improvements in and relating to barriers | |
ZA201908091B (en) | Indole-formamide derivative, preparation method therefor and use thereof in medicine | |
IL249453B (en) | Texapyrin conjugates and preparations - pt(iv) for use to overcome resistance to platinum | |
GB201614162D0 (en) | Antibodies, uses thereof and conjugates thereof | |
EP3632906C0 (en) | AZAARYL DERIVATIVE, PRODUCTION PROCESS THEREOF AND APPLICATION THEREOF FOR USE IN PHARMACY | |
IL266112A (en) | Antibodies against edb and antibody-drug conjugates | |
LT3544637T (lt) | Natyvių omv ir antigeno konjugatai bei jų naudojimo būdas | |
GB201717966D0 (en) | Immunotoxins, formulations thereof and their use in medicine | |
ZA201706254B (en) | Oil blends, processes for the preparation thereof and their use in formulas | |
FI20165821L (fi) | Menetelmä fysikaalisten suureitten mittaamiseksi ja menetelmässä hyödynnettävä mittausjärjestely | |
EP3385281A4 (en) | ANTIBODY FOR CROSS-LINKING TO HUMAN SEMA3A AND MOUSE, AND USE THEREOF | |
IL237283A0 (en) | Dldh and its derivatives, and preparations containing them for medical use | |
GB201709588D0 (en) | Carbocyclic derivatives and conjugated thereof, and their use in vaccines | |
Vandiver | Gravitas in Experience: Children's Artmaking Practice in School | |
GB201609866D0 (en) | Antibodies, uses thereof and conjugates thereof |